Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 12.17% is 298% above its 5-year average of -6.15%, near the high end of its 5-year range (-48.68%–25.64%).
41.37% above its 12-month average of 8.61%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 3.93%.
EBITDA MARGIN
12.17%
EBITDA MARGIN AVG TTM
8.61%
EBITDA MARGIN AVG 3Y
6.18%
EBITDA MARGIN AVG 5Y
-6.15%
EBITDA MARGIN AVG 10Y
-29.27%
EBITDA MARGIN AVG 15Y
-34.93%
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+41.37%
CURRENT VS 3Y AVG
+96.84%
CURRENT VS 5Y AVG
+297.94%
CURRENT VS 10Y AVG
+141.57%
CURRENT VS 15Y AVG
+134.84%
CURRENT VS 20Y AVG
N/A
Niagen Bioscience Inc
Market Cap
$213.84M
EBITDA Margin
12.17%
TTM Avg
8.61%
3Y Avg
6.18%
5Y Avg
-6.15%
Market Cap
$215.51M
EBITDA Margin
66.70%
TTM Avg
45.54%
3Y Avg
40.95%
5Y Avg
43.86%
Market Cap
$212.07M
EBITDA Margin
-847.24%
TTM Avg
-1408.92%
3Y Avg
-1408.92%
5Y Avg
-1408.92%
Market Cap
$216.06M
EBITDA Margin
-533986.11%
TTM Avg
-544963.54%
3Y Avg
-316138.98%
5Y Avg
-211520.31%
Market Cap
$208.49M
EBITDA Margin
43.70%
TTM Avg
-4.00%
3Y Avg
-127.66%
5Y Avg
-437.76%
Market Cap
$208.17M
EBITDA Margin
-646.93%
TTM Avg
-391.16%
3Y Avg
-256.59%
5Y Avg
-321.84%
Market Cap
$206.07M
EBITDA Margin
-2994.14%
TTM Avg
-1551.99%
3Y Avg
-854.53%
5Y Avg
-625.57%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Niagen Bioscience Inc (NAGE) | $213.84M | 12.17% | 8.61% | 6.18% | -6.15% |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.51M | 66.70% | 45.54% | 40.95% | 43.86% |
| Prelude Therapeutics Incorporated (PRLD)vs › | $212.07M | -847.24% | -1408.92% | -1408.92% | -1408.92% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $216.06M | -533986.11% | -544963.54% | -316138.98% | -211520.31% |
| Compugen Ltd. (CGEN)vs › | $208.49M | 43.70% | -4.00% | -127.66% | -437.76% |
| Alector, Inc. (ALEC)vs › | $208.17M | -646.93% | -391.16% | -256.59% | -321.84% |
| Sionna Therapeutics, Inc. (SION)vs › | $206.72M | N/A | N/A | N/A | N/A |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $206.07M | -2994.14% | -1551.99% | -854.53% | -625.57% |
| Pro-Dex, Inc. (PDEX)vs › | $205.90M | 18.55% | 18.23% | 16.57% | 15.69% |
| Electra Therapeutics Inc. (ETRA)vs › | $207.56M | N/A | N/A | N/A | N/A |
Gross Margin
64.2%
EBITDA Margin
12.2%
Operating Margin
6.7%
Net Margin
12.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 3.93% |
| 2026-03-31 | 5.93% |
| 2025-12-31 | 8.77% |
| 2025-09-30 | 13.04% |
| 2025-06-30 | 11.38% |
| 2025-03-31 | 16.86% |
| 2024-12-31 | 25.64% |
| 2024-09-30 | 7.69% |
| 2024-06-30 | 0.50% |
| 2024-03-31 | -1.54% |
| 2023-12-31 | 0.97% |
| 2023-09-30 | -3.59% |
| 2023-06-30 | -9.21% |
| 2023-03-31 | -6.77% |
| 2022-12-31 | -4.71% |
| 2022-09-30 | -15.33% |
| 2022-06-30 | -35.60% |
| 2022-03-31 | -41.62% |
| 2021-12-31 | -27.75% |
| 2021-09-30 | -48.68% |
| 2021-06-30 | -29.04% |
| 2021-03-31 | -47.37% |
| 2020-12-31 | -36.81% |
| 2020-09-30 | -26.93% |
| 2020-06-30 | -21.68% |
| 2020-03-31 | -38.49% |
| 2019-12-31 | -64.96% |
| 2019-09-30 | -53.81% |
| 2019-06-30 | -61.15% |
| 2019-03-31 | -79.62% |
| 2018-12-31 | -88.33% |
| 2018-09-30 | -103.05% |
| 2018-06-30 | -99.10% |
| 2018-03-31 | -125.17% |
| 2017-12-31 | -114.27% |
| 2017-09-30 | -49.08% |
| 2017-06-30 | -58.06% |
| 2017-03-31 | -48.10% |
| 2016-12-31 | -35.48% |
| 2016-09-30 | -20.94% |
| 2016-06-30 | 5.38% |
| 2016-03-31 | 7.47% |
| 2015-12-31 | -26.40% |
| 2015-09-30 | 4.16% |
| 2015-06-30 | -1.69% |
| 2015-03-31 | -15.76% |
| 2014-12-31 | -24.32% |
| 2014-09-30 | -14.09% |
| 2014-06-30 | -40.91% |
| 2014-03-31 | -57.91% |
| 2013-12-31 | -27.06% |
| 2013-09-30 | -43.49% |
| 2013-06-30 | -35.18% |
| 2013-03-31 | -57.07% |
| 2012-12-31 | -45.62% |
| 2012-09-30 | -39.83% |
| 2012-06-30 | -146.14% |
| 2012-03-31 | -242.91% |
| 2011-12-31 | -132.08% |
| 2011-09-30 | -125.72% |
| 2011-06-30 | -89.39% |
| 2011-03-31 | -41.26% |
| 2010-12-31 | -38.87% |
| 2010-09-30 | -49.55% |
| 2010-06-30 | -9.70% |
| 2010-03-31 | 6.80% |
| 2009-12-31 | -0.82% |
| 2009-09-30 | -5.34% |
| 2009-06-30 | -13.97% |
| 2009-03-31 | -15.29% |
| 2008-12-31 | -44.73% |
| 2008-09-30 | -56.44% |
| 2008-06-30 | -52.21% |
